Solasta Ventures
Home Approach Portfolio
News Team Hatchery Contact
HomeApproachPortfolio
Solasta Ventures
NewsTeamHatcheryContact
Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Nia JulianJuly 6, 2021
Facebook0 Twitter Pinterest0 0 Likes
Previous

Rallybio hits high gear as it targets $100M IPO to fund treatments for rare fetal bleeding disorder

Nia JulianJuly 12, 2021
Next

Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis

Nia JulianJune 30, 2021

© 2020 Solasta Ventures. All Rights Reserved.